EATG » Hepatitis

Hepatitis

Viral hepatitis kills as many as malaria, TB or HIV/AIDS, finds study

Viral hepatitis has become a leading cause of death and disability across the globe - killing as many people annually as TB, malaria or HIV/AIDS. This is the finding of…

Hepatitis B- and C-positive patients seem to carry higher risks for non-Hodgkin’s lymphoma

In an Italian case-control study with non-Hodgkin’s lymphoma (NHL) patients, researchers confirmed an increased risk for those positive for hepatitis C virus (HCV) and hepatitis B virus (HBV). The findings…

Grazoprevir plus ribavirin linked to rapid, sustained suppression of HCV RNA

The combination of grazoprevir plus ribavirin for 12 or 24 weeks demonstrated fast and sustained suppression of hepatitis C virus RNA in treatment-naive patients with hepatitis C virus genotype 1…

Diabetes is a risk factor for the development of liver cancer for people with cirrhosis successfully treated for HCV

Diabetes is a strong risk factor for hepatocellular carcinoma (HCC) in people with hepatitis C virus (HCV) infection who have received successful treatment for the infection, Swedish investigators report in…

Is a Cure for Hepatitis B Coming? Experts Say Yes

June 20, 2016 • By Hepatitis B Foundation Staff How far are we from finding a cure for hepatitis B? We are close, said Timothy Block, PhD, president and co-founder of the…

Euro-Canadian study looks at trends in liver cancer in co-infected people

Hepatitis C virus (HCV) and HIV have shared routes of infection. As a result, some people have both infections. This state is called co-infection. HCV infects the liver, and in…

FDA approves Gilead’s Epclusa® for the treatment of all genotypes of chronic hepatitis C

Epclusa is the first and only all-oral, pan-genotypic single tablet regimen for chronic hepatitis C virus infection and Gilead’s third sofosbuvir-based regimen FOSTER CITY, Calif.--Jun. 28, 2016-- Gilead Sciences, Inc.…

Gilead’s new hepatitis C drug approved by FDA, priced at $74,760

Epclusa is first treatment for all forms of the disease Drug will mainly be used in patients with genotypes 2 and 3 Gilead Sciences Inc.’s hepatitis C drug was approved…

Regulus reports clinical hold of RG-101

Timelines of on-going studies are not expected to be impacted LA JOLLA, Calif., June 27, 2016 -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company leading the discovery and development of…

Baraclude therapy for HBV leads to lower than expected HCC incidence

Patients with hepatitis B virus infection treated with Baraclude had an unexpected lower incidence of hepatocellular carcinoma over time, although the risk for hepatocellular carcinoma in this patient population still…